000101229 001__ 101229
000101229 005__ 20181203020748.0
000101229 022__ $$a0300-5208
000101229 037__ $$aARTICLE
000101229 245__ $$aThe problems of delivering neuroactive molecules to the CNS
000101229 260__ $$c1996
000101229 269__ $$a1996
000101229 336__ $$aJournal Articles
000101229 500__ $$aGene Therapy Center, Lausanne University Medical School, CHU Vaudois, Switzerland.
000101229 520__ $$aAt present, the aetiologies of many neurological and neurodegenerative diseases are unknown. However, emergence of a better understanding of these diseases, at both cellular and molecular levels, opens up the possibility of replacement therapies. The presence of the blood-brain barrier complicates the delivery of molecules to the central nervous system. Numerous attempts have been made to bypass this barrier either by delivering the drugs directly into the brain or by transplanting cells to produce the missing molecules in situ. This review explores several methods for delivering bioactive molecules into the CNS, including the use of permeabilizers, osmotic pumps, slow polymer release systems and transplantation of cells with or without the use of the encapsulation technology.
000101229 6531_ $$aAnimals
000101229 6531_ $$aCentral Nervous System/ metabolism
000101229 6531_ $$aDrug Administration Routes
000101229 6531_ $$aHumans
000101229 700__ $$aTan, S. A.
000101229 700__ $$0240206$$aAebischer, P.$$g104359
000101229 773__ $$j196$$q211-36; discussion 236-9$$tCiba Found Symp
000101229 909C0 $$0252067$$pLEN$$xU10457
000101229 909CO $$ooai:infoscience.tind.io:101229$$pSV$$particle
000101229 937__ $$aLEN-ARTICLE-1996-006
000101229 970__ $$a96/LEN
000101229 973__ $$aEPFL$$rREVIEWED$$sPUBLISHED
000101229 980__ $$aARTICLE